SLC34A2 is overexpressed in multiple cancer types, including lung, ovarian, and thyroid cancers [48] and identified as potential therapeutic target for non-small cell lung and Ovarian cancer [48]. This evidence concerns the gene SLC34A2 and thyroid gland carcinoma.